Abstract
We report the case of a 75-year old woman who received sorafenib (Nexavar), Bayer Pharmaceuticals Corporation, West Haven, CT) for a CNS relapse of clear cell renal cell carcinoma. After four months of sorafenib treatment, a brain magnetic resonance imaging showed 95%-volumetric regression of cerebral metastasis. To the best of our knowledge, this is the first almost complete resolution of brain metastases in renal cell carcinoma treated with sorafenib that has been described.
MeSH terms
-
Aged
-
Antineoplastic Agents / therapeutic use*
-
Benzenesulfonates / therapeutic use*
-
Brain Neoplasms / drug therapy*
-
Brain Neoplasms / secondary*
-
Carcinoma, Renal Cell / drug therapy
-
Carcinoma, Renal Cell / pathology*
-
Cerebral Cortex / drug effects
-
Cerebral Cortex / pathology
-
Female
-
Humans
-
Kidney Neoplasms / drug therapy
-
Kidney Neoplasms / pathology*
-
Magnetic Resonance Imaging
-
Niacinamide / analogs & derivatives
-
Phenylurea Compounds
-
Pyridines / therapeutic use*
-
Sorafenib
Substances
-
Antineoplastic Agents
-
Benzenesulfonates
-
Phenylurea Compounds
-
Pyridines
-
Niacinamide
-
Sorafenib